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Abstract
Background: Stavudine continues to be widely used in resource poor settings despite its toxicity. Our objective
was to determine association between plasma stavudine concentrations and lipoatrophy, concentrations of
glucose, lactate and triglycerides.
Methods: Participants were enrolled in a cross-sectional study with lipoatrophy assessment, oral glucose tolerance
test, fasting triglycerides, finger prick lactate, and stavudine concentrations. Individual predictions of the area under
the concentration curve (AUC) were obtained using a population pharmacokinetic approach. Logistic regression
models were fitted to assess the association between stavudine geometric mean ratio > 1 and impaired fasting
glucose, impaired glucose tolerance, hyperlactataemia, hypertriglyceridaemia, and lipoatrophy.
Results: There were 47 study participants with a median age of 34 years and 83% were women. The median body
mass index and waist:hip ratio was 24.5 kg/m
2 and 0.85 respectively. The median duration on stavudine treatment
was 14.5 months. The prevalence of lipoatrophy, impaired fasting glucose, impaired glucose tolerance,
hyperlactataemia, and hypertriglyceridaemia were 34%, 19%, 4%, 32%, and 23% respectively. Estimated median
(interquartile range) stavudine AUC was 2191 (1957 to 2712) ng*h/mL. Twenty two participants had stavudine
geometric mean ratio >1. Univariate logistic regression analysis showed no association between stavudine
geometric mean ratio >1 and impaired fasting glucose (odds ratio (OR) 2.00, 95% CI 0.44 to 9.19), impaired glucose
tolerance (OR 1.14, 95% CI 0.07 to 19.42), hyperlactataemia (OR 2.19, 95%CI 0.63 to 7.66), hypertriglyceridaemia (OR
1.75, 95%CI 0.44 to 7.04), and lipoatrophy (OR 0.83, 95% CI 0.25 to 2.79).
Conclusions: There was a high prevalence of metabolic complications of stavudine, but these were not associated
with plasma stavudine concentrations. Until there is universal access to safer antiretroviral drugs, there is a need for
further studies examining the pathogenesis of stavudine-associated toxicities.
Introduction
Stavudine is no longer recommended as part of first line
combination antiretroviral therapy (ART) because of a
high cumulative risk of toxicity, notably symptomatic
hyperlactataemia/lactic acidosis, lipoatrophy, and periph-
eral neuropathy [1,2]. In addition, stavudine causes
dyslipidaemia and insulin resistance, and is an indepen-
dent risk factor for the development of new onset dia-
betes mellitus [3]. Although the World Health
Organization (WHO) ART guidelines for resource-lim-
ited settings urge countries “to begin planning to move
away from stavudine-containing regimens” [4], stavudine
continues to be widely used in standardised first-line
regimens in low- and middle-income countries as it has
a low acquisition cost, is available in fixed dose
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tory monitoring for toxicity.
In 2006, WHO recommended reduced doses of stavu-
dine following the findings of a systematic review that
lower doses caused less toxicity without reducing effi-
cacy [1,5]. Most, if not all, of stavudine’s adverse drug
reactions are thought to be mediated by mitochondrial
toxicity and to be dose related [6,7]. Therefore it is rea-
sonable to assume that higher plasma concentrations of
stavudine might be associated with more toxicity. How-
ever, there are “no clear plasma concentration-effect
relationships” with nucleoside reverse transcriptase inhi-
bitors like stavudine, which are pro-drugs that require
intracellular tri-phosphorylation for antiviral activity [8].
A retrospective study from the Netherlands reported a
correlation between lipoatrophy and higher stavudine
plasma concentrations [9], but data correlating stavudine
plasma concentrations with other metabolic adverse
drug reactions are lacking.
We investigated whether there was an association
between stavudine plasma concentrations and lipoatro-
phy or concentrations of glucose, lactate and triglyceride
in a population where stavudine use is likely to be wide-
spread in the medium term: African HIV-infected
adults.
Methods
Study design and participants
We conducted a prospective cross sectional study
between February 2007 and January 2008. Ambulatory
HIV-infected African black adults who presented for a
routine follow up visit at public sector antiretroviral
clinics in Cape Town were recruited by convenient
sampling. Participants were eligible if they were on sta-
vudine-based therapy for a minimum of 6 months. Par-
ticipants with renal or hepatic disease, active
opportunistic infections, known diabetes or dyslipidae-
mia, or self-reported non-adherence were excluded. All
participants gave informed consent. The University of
Cape Town research ethics committee approved the
study.
Clinical and laboratory evaluations
Participants fasted overnight and underwent an oral glu-
cose tolerance test (OGTT). Impaired fasting glucose
(IFG), impaired glucose tolerance (IGT) and diabetes
were defined according to the American Diabetes Asso-
ciation criteria [10]. Fasting triglycerides were deter-
mined at 0 min of the OGTT. Hypertriglyceridaemia
was defined according to the NCEP III criteria [11]. Fin-
ger prick lactate was measured before the glucose load-
ing using the Accutrend® lactate meter (Roche, Basel,
Switzerland). Hyperlactataemia was defined as a lactate
concentration greater or equal to 2.5 mmol/L.
Lipoatrophy was determined by self-reported periph-
eral fat loss using a validated questionnaire [12]. Lipoa-
trophy was rated as absent (score = 0), mild (noticeable
on close inspection, score = 1), moderate (readily
noticeable by participant, score = 2) or severe (readily
noticeable to a casual observer, score = 3) in each of
four areas (face, arms, legs and buttocks). The lipoatro-
phy score could range from 0 to 12. Lipoatrophy was
regarded to be present if the score was 1 or above.
Self reported adherence was determined using a stan-
dard 4-day adherence questionnaire administered by
trained field workers [13]. We reviewed medical records
to determine duration on antiretroviral therapy and cur-
rent CD4+ lymphocyte counts and viral load. Current
CD4+ count was regarded as the count measured within
3 months of the study visit.
We measured plasma stavudine concentrations at 0,
30, and 120 minutes of the OGTT. We collected the
blood samples using heparinised tubes that were imme-
diately placed on ice until centrifugation within 4 hours,
and then kept in a minus 80°C freezer until analysis.
Stavudine was assayed by liquid chromatography tan-
dem mass spectrometry using a validated method on an
API 4000 mass spectrometer. The mobile phase con-
sisted of gradient of acetonitrile and 0.5% glacial acetic
acid. Chromatography was performed on a Phenomonex
Synergi fusion C18 column maintained at 25°C. Reser-
pine was used as an internal standard. 50 μL of each
sample was precipitated with acetonitrile containing the
internal standard, centrifuged and 5 μLo ft h es u p e r n a -
tant injected onto the column. Standard curves in the
range 0.02 - 6 μg/mL and appropriate quality control
samples were run with each batch. The lower limit of
quantification was 20 ng/mL. Inter- and intra-day coeffi-
cients of variation were below 9% for all quality control
samples.
Pharmacokinetic analysis
The aim of the pharmacokinetic analysis was to obtain a
prediction of each participant’s apparent stavudine clear-
ance (CL/F) for calculation of the area under the con-
centration curve (AUC), where AUC = dose (ng)/
clearance (L/h). The data were analysed using nonlinear
mixed effects modelling with NONMEM® (version VI
level 2.0; ICON Development Solutions, Ellicott City,
MD, USA). Given the sparse data (1-3 observations per
participant), a model developed using rich stavudine
concentration data from a separate study our group has
conducted of African adults from the same community
was used [14]. The population pharmacokinetic para-
meter estimates were fixed to: apparent clearance 17.8
L/h/70 kg
3/4 (between subject variability 17%CV), appar-
ent volume of distribution 33.5 L/kg, first-order absorp-
tion rate constant 11.1/h (between subject variability
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dual variability 27% and additive residual variability 10
ng/mL. Individual pharmacokinetic parameter sets were
then obtained using Bayesian estimation given these
model parameters and the observed data. The geometric
mean ratio (GMR) was calculated by comparing the
individual log-transformed AUC to the mean log-trans-
formed AUC of the overall population.
Statistical analysis
Means (standard deviation (S.D)) and medians (inter-
quartile range) were used to describe parametric data
and non-parametric data, respectively. Categorical data
were compared using c
2 test (or Fisher’s exact test), and
continuous data were compared using student’sT - t e s t
or Mann-Whitney test, whichever was appropriate.
Logistic regression models were fitted to assess the asso-
ciation between GMR > 1 and IFG, IGT, hyperlactatae-
mia, hypertriglyceridaemia and lipoatrophy. Linear
regression models were fitted to assess the association
between log-transformed stavudine area under the curve
and the following variables: concentrations of glucose,
lactate and triglycerides, and lipoatrophy scores. All
tests were two-sided, and a P-value < 0.05 was consid-
ered significant. Analyses were performed using SPSS
(version 17, SPSS Inc, Chicago, Illinois, USA)
Results
Forty seven black participants were included for the ana-
lysis. Median (IQR) age was 34 (30-38) years. Thirty nine
participants were female. Median (IQR) weight and body
mass index were, 61.0 (54.4 to 73.8) kg and 24.5 (21.5 to
30.4) kg/m
2, respectively. Median waist to hip ratio was
0.85 (0.80 to 0.92). Median (IQR) current CD4 count was
304 (234-516) cells/μL. Twelve participants were virologi-
cally suppressed, 6 had viral load above 50 copies/mL and
29 had no viral load data. Forty and seven participants
were on 30 mg and 40 mg of stavudine, respectively.
Twenty six, twenty and one participants were on efavir-
enz, nevirapine and lopinavir, respectively. All partici-
pants were on lamivudine. The median (interquartile
range (IQR)) fasting glucose concentration was 4.9 (4.7
to 5.4) mmol/L and the mean (standard deviation (sd)) 2
hour glucose concentration was 5.34 (1.43) mmol/L.
Nine and two participants had IFG and IGT, respectively.
The mean (sd) lactate concentration was 2.26 (0.78)
mmol/L and 15 participants had hyperlactataemia. The
median (IQR) triglyceride concentration was 1.17 (0.85
to 1.60) mmol/L and 11 participants had hypertriglyceri-
daemia. The median (IQR) lipoatrophy score was 0 (0 to
9) and 16 patients had lipoatrophy.
A total of 122 stavudine concentrations from 47 parti-
cipants were analysed. Eleven participants had no pre-
dose concentrations because they took their stavudine
morning doses prior to the OGTT. The observed stavu-
dine concentrations plotted against the model predic-
t i o n sa r es h o w ni nF i g u r e1 .S t a v u d i n ee x p o s u r ew a s
expressed with the calculated AUC. The median (inter-
quartile range) stavudine AUC was 2191 (1957 to 2712)
ng*h/mL. The mean (standard deviation) log-trans-
formed AUC was 3.36 ± 0.10 ng*h/mL. 22 participants
had a GMR greater than 1.
Figure 1 Plasma stavudine concentrations vs time after dose, collected during OGTT in 47 HIV-1 infected participants.O G T T=o r a l
glucose tolerance test, d4T = stavudine. The solid line indicates the median predicted concentrations and the dashed lines the 90% prediction
interval of a model developed using rich stavudine concentration-time data. The lower limit of quantification (20 ng/mL) is shown by a dotted
line. Open circles indicate stavudine concentrations when stavudine was taken before the OGTT, and the solid diamonds are stavudine
concentrations collected when the stavudine dose was taken during the OGTT (i.e. the 0-hour OGTT was collected pre-dose).
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vudine AUC and metabolic parameters expressed as
continuous variables (Table 1). We also showed no asso-
ciation between stavudine geometric mean ratio >1 and
abnormal metabolic parameters expressed as categorical
variables (Table 2). We found an association between
duration and triglycerides concentrations (beta coeffi-
cient 95%CI = 0.02 (0.01 to 0.04) p = 0.004. No signifi-
cant association was found between duration and
glucose and lactate concentrations as well as lipoatrophy
scores.
Discussion
Despite guidelines recommending that the use of stavu-
dine be avoided because of its toxicity, it continues to
play a critical role in scaling up antiretroviral therapy in
resource poor settings. Therefore, studies examining
pathogenesis of stavudine toxicity are still relevant. We
found no association between stavudine AUC and the
lipoatrophy scores or concentrations of glucose, lactate
and triglycerides. To our knowledge this is the first
study to evaluate the association between plasma stavu-
dine concentrations and serum glucose, lactate and tri-
glycerides. We found high prevalence of metabolic
abnormalities in this black African cohort with a median
duration of stavudine exposure of 14.5 months: lipoatro-
phy (34%), dysglycaemia (23%), hyperlactataemia (32%),
and hypertriglyceridaemia (23%). We found an associa-
tion between duration and triglycerides concentrations.
A meta-analysis from randomised control trials and
cohort studies showed that switching from higher to
lower doses of stavudine, or starting at lower doses, is
associated with improvement in stavudine toxicity with-
out loss of efficacy [5]. Switching to lower doses of sta-
vudine was associated with decreased drug exposure,
mitochondrial DNA repletion, partial reversal of lipoa-
trophy, improvement in lactate and lipids [5,15,16].
Therefore, stavudine toxicity is dose related. The lack of
an association between stavudine AUC and all the meta-
bolic abnormalities that we found can be explained as
follows: First, like all nucleoside/nucleotide reverse tran-
scriptase inhibitors (NRTIs), stavudine is a pro-drug
that must be converted intracellularly into its tripho-
sphate moiety (d4T-TP) to exert antiviral activity by
competing with endogenous nucleotides to terminate
HIV replication [17]. The d4T-TP also inhibits mito-
chondrial DNA polymerase gamma in a dose dependent
manner in cells of various tissues, and effectively termi-
nates mitochondrial replication with subsequent mito-
chondrial damage or depletion: the common pathway
for stavudine related toxicity. Intracellular triphosphate
concentrations, but not NRTI parent drugs, have gener-
ally been shown to have a good correlation with anti-
viral activity [17-21], as well as toxicity [22]. The
cellular processes that affect the relationship between
plasma NRTI and intracellular triphosphate concentra-
tions include variation in expression of drug transpor-
ters, rate limiting steps or saturated phosphorylation
steps, cell activation state, and drug interactions [17,19].
Second, clinical manifestations of stavudine toxicity are
also influenced by host susceptibility such as age, sex,
advanced HIV disease and genetic susceptibility
[17,23-26]. Third, it seems that stavudine toxicity is
cumulative, as it is shown to be dose related and is asso-
ciated with prolonged duration on treatment [5,9,15,16].
Therefore, differences in plasma concentrations, if they
exist, are likely to be small, and a very large study will
be needed to detect the difference.
Although stavudine related toxicity is well documen-
ted, to date, few studies have investigated pharmacoki-
netic relationship with stavudine toxicity. Our findings
are different to a case-control study conducted by ter
Hofstede et al, which reported that cases with lipoatro-
phy had higher stavudine exposure than controls [9].
However, there were no statistically significant differ-
ences in geometric means of concentration ratios
between the cases and controls. The discrepancy
between their findings and ours could possibly be
explained by differences in study design and participant
selection. Ter Hofstede et al conducted a retrospective
study. Exposure was represented by a time-adjusted con-
centration ratios derived from a historic population. In
contrast, our study was conducted prospectively and we
used stavudine AUC derived from individual clearances
obtained from a pharmacokinetic model of intensively
sampled participants from the same community [14].
The estimated AUC of 2191 ng*h/mL in our population
Table 1 Univariate linear regression analysis of stavudine
log-transformed AUC and metabolic parameters
Variable Beta coefficient (95% CI) p-value
Fasting glucose -0.02 (-0.06 to 0.04) 0.54
2 hour glucose -0.02 (-0.04 to 0.00) 0.09
Lactate 0.00 (-0.04 to 0.04) 0.91
Triglycerides 0.00 (-0.05 to 0.05) 1.00
Lipoatrophy score -0.00 (-0.01 to 0.01) 0.37
Table 2 Univariate logistic regression analysis of
stavudine geometric mean ratio >1 and metabolic
parameters
Variable Odds ratio (95%CI) p-value
Impaired fasting glucose 2.00 (0.44 to 9.19) 0.37
Impaired glucose tolerance 1.14 (0.07 to 19.42) 0.93
Hyperlactataemia 2.19 (0.63 to 7.66) 0.22
Hypertriglyceridaemia 1.75 (0.44 to 7.04) 0.43
Lipoatrophy score >0 0.83 (0.25 to 2.79) 0.83
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c a np o p u l a t i o nw eu s e df o rt h ep o p u l a t i o nm o d e l[ 1 4 ]
and to control patients from the US [27], but is higher
than reported in Indian patients [28] or the Summary of
Product Characteristics of Zerit [29]. It is possible that
stavudine exposure is high in our population, which
may account for the high prevalence of metabolic
abnormalities we observed. However, the prevalence of
metabolic abnormalities on stavudine-containing regi-
mens that we found were comparable to other published
studies with variable duration of follow-up and different
additional antiretroviral drugs: lipoatrophy (20-42%)
[30-33], dysglycaemia (3-25%) [34], hyperlactataemia
(15-35%) [35], and hypertriglyceridaemia (22-71%)
[36,37]. We found an association between duration and
triglycerides concentrations and this has been reported
before [36].
Our study had a few limitations. First, we measured
stavudine concentrations in plasma and not the active
intracellular triphosphorylated metabolite. Second, we
used sparse sampling instead of intensive sampling.
However, a population approach allowed us to predict
individual AUCs, an acceptable measure of drug expo-
sure. Third, we did not have data on genetic polymorph-
isms. Fourth, sample size of this study was small, and
therefore might have insufficient power to detect rela-
tively small effects of plasma concentrations on meta-
bolic abnormalities. However, this sample size is larger
than in other pharmacokinetic studies that have exam-
ined the association between stavudine concentrations
and metabolic toxicity [9,22].
Future studies examining the pathogenesis of stavu-
dine-associated toxicities should have adequate power
and preferably be longitudinal. Relevant genetic studies
should also be done in the populations where stavudine
will still be used in the medium term. Physiologically
based pharmacokinetic models that take into account the
temporal fluctuations and intracellular cascade steps of
plasma NRTIs and metabolites should be used to estab-
lish pharmacokinetic-pharmacodynamic relationships.
In conclusion, we did not find an association between
stavudine exposure and metabolic complications.
Despite guidelines recommending that the use of stavu-
dine be avoided because of its toxicity, it is still widely
used in resource poor settings. Until there is universal
access to safer drugs, there is a need for further studies
examining the pathogenesis of stavudine-associated
toxicities.
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